CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates

Tatsuo Kawai, Hiroshi Sogawa, Svetlan Boskovic, Gregory Abrahamian, Rex Neal Smith, Siew Lin Wee, David Andrews, Ognjenka Nadazdin, Ichiro Koyama, Megan Sykes, Henry J. Winn, Robert B. Colvin, David H. Sachs, A. Benedict Cosimi

Resultado de la investigación: Articlerevisión exhaustiva

172 Citas (Scopus)


Costimulatory blockade with anti-CD154 monoclonal antibody (aCD154) prolongs allograft survival in non-human primates, but has not reliably induced tolerance when used alone. In the current studies, we evaluated the effect of adding CD154 blockade to a chimerism inducing nonmyeloablative regimen in primates. We observed a significant improvement of donor bone marrow (DBM) engraftment, which has been associated with a lower incidence of acute rejection and long-term survival of renal allografts without the need for previously required splenectomy. Among the long-term survivors, four never showed evidence of rejection, with the longest survival exceeding 1700 days following discontinuation of immunosuppression. Nevertheless, late chronic rejection was observed in three of eight recipients, indicating the necessity of further modifications of the regimen. Control recipients receiving no DBM or donor splenocytes in place of DBM rejected their allografts. Thus, DBM engraftment with, at least, transient mixed chimerism appears essential for induction of allograft tolerance using this conditioning regimen. Modification of the original mixed chimerism approach, by the addition of costimulatory blockade, has been shown to enhance mixed chimerism and induce renal allograft tolerance with less morbidity in nonhuman primates.

Idioma originalEnglish (US)
Páginas (desde-hasta)1391-1398
Número de páginas8
PublicaciónAmerican Journal of Transplantation
EstadoPublished - sept 2004
Publicado de forma externa

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Profundice en los temas de investigación de 'CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates'. En conjunto forman una huella única.

Citar esto